https://allsci.com/news/biotech/addex-gabab-portfolio-indivior-regains-from-as/ AllScien 2026-09-25T17:19:30.402012Z Indivior exits Addex partnership, returns GABAB portfolio rights https://allsci.com/news/biotech/bighat-biosciences-series-c-funding-raises-usd/ AllScien 2026-09-25T17:15:42.917742Z BigHat Bio raises USD 75m Series C as AI-designed protein therapeutics advance https://allsci.com/news/approvals/welireg-lenvima-fda-approval-approves-plus-for/ AllScien 2026-09-25T16:18:40.542754Z Merck, Eisai win FDA approval for Welireg-Lenvima in advanced RCC https://allsci.com/news/licensing-and-partnerships/novo-nordisk-nanexa-license-licenses-nanexas/ AllScien 2026-09-25T14:55:25.427589Z Novo licenses Nanexa's long-acting injectable platform for obesity and diabetes drugs https://allsci.com/news/biotech/lecanemab-alzheimers-response-alamars-proteomics/ AllScien 2026-09-25T13:45:03.879660Z Proteomic study finds divergent biological responses to lecanemab treatment https://allsci.com/news/biotech/kqtd-126-ind-application-xtalpi-submits-for/ AllScien 2026-09-25T12:46:48.793537Z XtalPi files first proprietary IND for gut-restricted pan-TRK inhibitor KQTD-126 https://allsci.com/news/business/lundbeck-relocates-boston-headquarters-us-greater/ AllScien 2026-09-25T10:35:12.404751Z Lundbeck relocates US headquarters to Greater Boston for innovation hub https://allsci.com/news/biotech/fda-clearance-bispecific-antibody-systimmune/ AllScien 2026-09-25T10:30:59.526854Z SystImmune clears FDA IND for SI-B037 bispecific using NAM-based toxicology package https://allsci.com/news/development/lyrfigtu-fda-approval-cholangiocarcinoma-1/ AllScien 2026-09-24T18:23:28.190121Z Elevar wins FDA approval for FGFR2 inhibitor Lyrfigtu